(Q77300551)
Statements
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group (English)
1 September 1998
scientific article published on 01 September 1998